To reach the next value inflection
LicenseRx asset brief
Gene-signature for Predicting Immune-Related Adverse Events (irAEs) After Immune Checkpoint Inhibitor (ICI) Treatment
Probability of Success
16% · grade C · Medium data confidence
Model PoS 16% (grade C, medium data confidence). Strongest signals: Indication pull, Modality feasibility. Biggest drag: Translational evidence.
Data maturity (22%)
39
Early / Discovery; biomarker readout.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
80
Diagnostic/biomarker -- can monetize via service before full approval.
Indication pull (14%)
81
Oncology, Immunology -- active buyer appetite.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: biomarker.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →